These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10373167)

  • 1. Universal HIV screening of pregnant women in England: cost effectiveness analysis.
    Postma MJ; Beck EJ; Mandalia S; Sherr L; Walters MD; Houweling H; Jager JC
    BMJ; 1999 Jun; 318(7199):1656-60. PubMed ID: 10373167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening.
    Mauskopf JA; Paul JE; Wichman DS; White AD; Tilson HH
    JAMA; 1996 Jul; 276(2):132-8. PubMed ID: 8656505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago.
    Immergluck LC; Cull WL; Schwartz A; Elstein AS
    Pediatrics; 2000 Apr; 105(4):E54. PubMed ID: 10742375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy.
    Myers ER; Thompson JW; Simpson K
    Obstet Gynecol; 1998 Feb; 91(2):174-81. PubMed ID: 9469271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of universal antenatal screening for HIV in New Zealand.
    Bramley D; Graves N; Walker D
    AIDS; 2003 Mar; 17(5):741-8. PubMed ID: 12646798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands.
    Rozenbaum MH; Verweel G; Folkerts DK; Dronkers F; van den Hoek JA; Hartwig NG; de Groot R; Postma MJ
    Int J STD AIDS; 2008 Oct; 19(10):668-75. PubMed ID: 18824618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal antenatal human immunodeficiency virus (HIV) testing programme is cost-effective despite a low HIV prevalence in Hong Kong.
    Lee PM; Wong KH
    Hong Kong Med J; 2007 Jun; 13(3):199-207. PubMed ID: 17548908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
    Rely K; Bertozzi SM; Avila-Figueroa C; Guijarro MT
    Health Policy Plan; 2003 Sep; 18(3):290-8. PubMed ID: 12917270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Saba J
    AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention.
    Gorsky RD; Farnham PG; Straus WL; Caldwell B; Holtgrave DR; Simonds RJ; Rogers MF; Guinan ME
    Public Health Rep; 1996; 111(4):335-41. PubMed ID: 8711101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam].
    Postma MJ; van den Hoek JA; Beck EJ; Heeg B; Jager JC; Coutinho RA
    Ned Tijdschr Geneeskd; 2000 Apr; 144(16):749-54. PubMed ID: 10812443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
    Wilkinson D; Floyd K; Gilks CF
    S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who should be screened for HIV infection? A cost-effectiveness analysis.
    McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA
    Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparison of three screening strategies for prevention of perinatal HIV infection in Colombia: a decision analysis model].
    Gómez M
    Rev Panam Salud Publica; 2008 Oct; 24(4):256-64. PubMed ID: 19133174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness analysis of antenatal HIV screening in United Kingdom.
    Ades AE; Sculpher MJ; Gibb DM; Gupta R; Ratcliffe J
    BMJ; 1999 Nov; 319(7219):1230-4. PubMed ID: 10550083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of expanded antenatal HIV testing in London.
    Postma MJ; Beck EJ; Hankins CA; Mandalia S; Jager JC; de Jong-van den Berg LT; Walters MD; Sherr L
    AIDS; 2000 Oct; 14(15):2383-9. PubMed ID: 11089627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care.
    Grobman WA; Garcia PM
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 1):1062-71. PubMed ID: 10561619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting.
    Mansergh G; Haddix AC; Steketee RW; Nieburg PI; Hu DJ; Simonds RJ; Rogers M
    JAMA; 1996 Jul; 276(2):139-45. PubMed ID: 8656506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States.
    Zaric GS; Bayoumi AM; Brandeau ML; Owens DK
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):403-16. PubMed ID: 11141240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.